Single Dose Oral Baloxavir Well-Tolerated in Pediatric Influenza
Baloxavir marboxil was well-tolerated in a pediatric population and rapidly reduced viral titers.
Emerging Treatments
Baloxavir Marboxil Approved for Patients at High Risk of Flu-Related Complications
The FDA has approved a supplemental NDA for Xofluza for the treatment of acute, uncomplicated influenza in patients aged 12 years and older.
Tesamorelin May Aid Patients With HIV, Fatty Liver Disease
Tesamorelin reduces liver fat content in patients with HIV and nonalcoholic fatty liver disease.
FDA Panel Votes on Novel Antibiotic for Complicated UTI
The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of approval of cefiderocol for the treatment of complicated UTIs including pyelonephritis.
Emtricitabine and Tenofovir Alafenamide Combination for HIV-1 PrEP Gets FDA Approval
The FDA has approved Descovy for HIV-1 PrEP in at-risk adults and adolescents (≥35kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at-risk from receptive vaginal sex.
Oral Amphotericin B Formulation Gets Orphan Drug Status for Cryptococcosis
The Food and Drug Administration (FDA) has granted Orphan Drug designation to MAT2203 (Matinas BioPharma) for the treatment of cryptococcosis.
Length of Hospital Stay Improved With Dalbavancin Therapy in ABSSSI
Length of stay for ABSSSI hospital admissions were significantly improved after implementing dalbavancin therapy with the ENHANCE ABSSSI trial.
Efficacy of Lefamulin vs Moxifloxacin for Legionella CABP
Lefamulin appears to be noninferior in safety and efficacy compared with moxifloxicin in the treatment of community-acquired bacterial pneumonia.
Delafloxacin Effectively Treats Community-Acquired Bacterial Pneumonia in Patients With Diabetes
Researchers conducted a Phase 3 trial of patients with community acquired bacterial pneumonia and diabetes to compare delafloxacin treatment with moxiflocacin.
Ceftaroline Approved for Younger Patients to Treat Acute Bacterial Skin/Skin Structure Infections
The FDA has expanded the indication for Teflaro to include treatment of ABSSSI in pediatric patients from birth to less than 2 months of age.
Next post in Pediatric Illnesses
